Adenovirus-mediated anti-sense ERK2 gene therapy inhibits tubular epithelial-mesenchymal transition and ameliorates renal allograft fibrosis

Transplant Immunology

Volumn 25, Issue 1, 2011, Pages 34-41

  Ding, Zhao ^a,b   Chen, Zhishui ^a   Chen, Xilin ^a   Cai, Ming ^a   Guo, Hui ^a   Chen, Xiaoping ^a   Gong, Nianqiao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Adenovirus mediated anti sense ERK2 (Adanti ERK2) gene therapy; Epithelial mesenchymal transition (EMT); Extracellular signal regulated kinase (ERK); Renal allograft fibrosis; Renal transplantation

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MACROPHAGE MIGRATION INHIBITION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RAT; RENAL GRAFT DYSFUNCTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; DNA, ANTISENSE; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; GENE THERAPY; GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959666426     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.04.001     Document Type: Article

References (48)

1. Bedi S., Vidyasagar A., Djamali A. Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 2008, 22:1-5.
2. Nankivell B.J., Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006, 81:643-654.
3. Racusen L.C., Solez K., Colvin R.B., Bonsib S.M., Castro M.C., Cavallo T., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999, 55:713-723.
4. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of Chronic Allograft Nephropathy ('CAN'). Am J Transplant 2007, 7:518-526.
5. Gong N., Chen X., Ding Z., Ming C., Chen X. Chronic allograft nephropathy: the mechanism and strategies. Hong Kong J Nephrol 2007, 9:58-69.
6. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333.
7. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004, 15:1-12.
8. Hertig A. Epithelial-mesenchymal transition of the renal graft. Nephrol Ther 2008, 4:S25-S28.
9. Burns W.C., Kantharidis P., Thomas M.C. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007, 185:222-231.
10. Yang J., Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001, 159:1465-1475.
11. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
12. Wang S., Jiang J., Guan Q., Wang H., Nguan C.Y., Jevnikar A.M., et al. Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling. Am J Physiol Renal Physiol 2008, 295:F672-F679.
13. Bost F., Aouadi M., Caron L., Even P., Belmonte N., Prot M., et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005, 54:402-411.
14. Vantaggiato C., Formentini I., Bondanza A., Bonini C., Naldini L., Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 2006, 5:14.
15. Chen X., Chen Z., Ding Z., Dong C., Guo H., Gong N. Antisense extracellular signal-regulated kinase-2 gene therapy inhibits platelet-derived growth factor-induced proliferation, migration and transforming growth factor-β1 expression in vascular smooth muscle cells and attenuates transplant vasculopathy. Transpl Int 2008, 21:30-38.
16. Gong N., Pleyer U., Volk H.D., Ritter T. Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther 2007, 14:484-490.
17. Gong N., Pleyer U., Yang J., Vogt K., Hill M., Anegon I., et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 2006, 8:459-467.
18. Gong N., Pleyer U., Vogt K., Anegon I., Flügel A., Volk H.D., et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci 2007, 48:1043-1052.
19. Tilney N.L., Whitley W.D., Tullius S.G., Heemann U.W., Wasowska B., et al. Serial analysis of cytokines, adhesion molecule expression, and humoral responses during development of chronic kidney allograft rejection in a new rat model. Transplant Proc 1993, 25:861-862.
20. Tullius S.G., Hancock W.W., Heemann U., Azuma H., Tilney N.L. Reversibility of chronic renal allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 1994, 15:93-99.
21. Ritter T., Lehmann M., Volk H.D. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 2002, 16:3-10.
22. Yang J., Reutzel-Selke A., Steier C., Jurisch A., Tullius S.G., Sawitzki B., et al. Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-γaccelerates chronic graft injury in a rat renal allograft model. J Am Soc Nephrol 2003, 14:214-225.
23. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999, 10:2013-2017.
24. Liu B.C., Li M.X., Zhang J.D., Liu X.C., Zhang X.L., Phillips A.O. Inhibition of integrin-linked kinase via a siRNA expression plasmid attenuates connective tissue growth factor-induced human proximal tubular epithelial cells to mesenchymal transition. Am J Nephro 2008, 28:143-151.
25. Lee S. An improved technique of renal transplantation in the rat. Surgery 1967, 61:771-773.
26. Saito S., Frank G.D., Motley E.D., Dempsey P.J., Utsunomiya H., Inagami T., et al. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 2002, 294:1023-1029.
27. Burns W.C., Twigg S.M., Forbes J.M., Pete J., Tikellis C., Thallas-Bonke V., et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006, 17:2484-2494.
28. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
29. Meindl-Beinker N.M., Dooley S. Transforming growth factor-beta and hepatocyte transdifferentiation in liver fibrogenesis. J Gastroenterol Hepatol 2008, 23(Suppl. 1):S122-S127.
30. Zeisberg M., Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004, 82:175-181.
31. Chen L., Liu B.C., Zhang X.L., Zhang J.D., Liu H., Li M.X. Influence of connective tissue growth factor antisense oligonucleotide on angiotensin II-induced epithelial mesenchymal transition in HK2 cells. Acta Pharmacol Sin 2006, 27:1029-1036.
32. Ito Y., Goldschmeding R., Bende R., Claessen N., Chand M., Kleij L., et al. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 2001, 12:472-484.
33. Yokoi H., Mukoyama M., Sugawara A., Mori K., Nagae T., Makino H., et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002, 282:F933-F942.
34. Roestenberg P., van Nieuwenhoven F.A., Wieten L., Boer P., Diekman T., Tiller A.M., et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004, 27:1164-1170.
35. Cheng O., Zhang X., Usinger W., Molineaux C., Mannon R.B. Connective tissue growth factor (CTGF): a novel effector of chronic allograft nephropathy (CAN). J Am Soc Nephrol 2002, 13:24A.
36. Nagae T., Mori K., Mukoyama M., Kasahara M., Yokoi H., Suganami T., et al. Adrenomedullin inhibits connective tissue growth factor expression, extracellular signal-regulated kinase activation and renal fibrosis. Kidney Int 2008, 74:70-80.
37. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008, 68:7846-7854.
38. Liu Q., Mao H., Nie J., Chen W., Yang Q., Dong X., et al. Transforming growth factor {beta}1 induces epithelial-mesenchymal transition by activating the JNK-Smad3 pathway in rat peritoneal mesothelial cells. Perit Dial Int 2008, 28(Suppl. 3):S88-S95.
39. Whitehurst A.W., Robinson F.L., Moore M.S., Cobb M.H. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem 2004, 279:12840-12847.
40. Park J.H., Lee M.Y., Heo J.S., Han H.J. A potential role of connexin 43 in epidermal growth factor-induced proliferation of mouse embryonic stem cells: involvement of Ca2+/PKC, p44/42 and p38 MAPKs pathways. Cell Prolif 2008, 41:786-802.
41. Farrokhnia N., Ericsson A., Terént A., Lennmyr F. MEK-inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat. Eur J Clin Invest 2008, 38:679-685.
42. Dong C., Gong N., Chen Z., Chen X., Xu Q., Guo H., et al. Antisense ERK1/2 oligodeoxynucleotide gene therapy attenuates graft arteriosclerosis of aortic transplant in a rat model. Transplant Proc 2006, 38:3304-3306.
43. Gong N., Ming C., Guo H., Chen Z. The clinical pathological characteristics and immunosuppressant conversion treatment of chronic allograft nephropathy. Chin J Organ Transplant 2007, 28:420-424. in Chinese.
44. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
45. Gobe G.C., Johnson D.W. Distal tubular epithelial cells of the kidney: potential support for proximal tubular cell survival after renal injury. Int J Biochem Cell Biol 2007, 39:1551-1561.
46. Sharples E.J. Acute kidney injury: stimulation of repair. Curr Opin Crit Care 2007, 13:652-655.
47. Robertson H., Ali S., McDonnell B.J., Burt A.D., Kirby J.A. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004, 15:390-397.
48. Zhang Y.L., Dong C. MAP kinases in immune responses. Cell Mol Immunol 2005, 2:20-27.